Anaferon 20 pcs. lozenges

Anaferon® is indicated for use in adults.
Treatment and prevention of influenza and acute respiratory viral infections (ARVI) as part of combination therapy.
Comprehensive treatment of newly diagnosed and recurrent herpes simplex labialis and genital herpes.

The tablet is not intended to be divided.
For oral use, not during meals. Hold the tablet in the mouth until fully dissolved.
Acute respiratory viral infections (ARVI), influenza, herpes simplex
On the first day of treatment, take 8 tablets according to the following scheme:
1 tablet every 30 minutes for the first 2 hours (a total of 5 tablets in 2 hours), then take 1 tablet 3 more times at equal intervals throughout the same day. On the 2nd day and thereafter, take 1 tablet 3 times a day until full recovery.
If there is no improvement by the third day of treatment for acute respiratory viral infections and influenza, consult a doctor.
For prophylactic purposes, take the medication daily once a day for 1-3 months.
Genital herpes
For acute manifestations of genital herpes, take the medication at equal intervals according to the following scheme: Days 1-3 - 1 tablet 8 times a day, then 1 tablet 4 times a day for at least 3 weeks.
For the prevention of recurrences of chronic herpes virus infection - 1 tablet per day. The recommended duration of the prophylactic course is determined individually and may last up to 6 months.

1 tablet contains:
Active ingredient:
affinity-purified antibodies to human gamma interferon - 10,000 UMD*.
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

• UMD - units of modifying action.

Tablets of a flat-cylindrical shape, with a score and bevel, from white to almost white in color. The flat side with the score is imprinted with the inscription MATERIA MEDICA, while the other flat side bears the inscription ANAFERON.

Increased individual sensitivity to the components of the drug.
Age under 18 years.
Lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption.

Pregnancy and lactation
The safety of using Anaferon® in pregnant women and during lactation has not been studied. If the drug is required, the benefit-risk ratio should be considered.

The preparation contains lactose monohydrate, therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome, or congenital lactase deficiency.
Effect on the ability to drive vehicles and operate machinery
Data on the effect on the ability to drive vehicles and operate machinery is not available.

Allergic reactions and manifestations of increased individual sensitivity to the components of the drug are possible.

In case of overdose, dyspeptic symptoms may occur due to the excipients contained in the preparation.
Treatment: symptomatic.

No cases of incompatibility with other medications have been identified to date.
If necessary, the drug can be combined with other antiviral, antibacterial, and symptomatic agents.

In preventive and therapeutic use, the drug exhibits immunomodulatory and antiviral effects. Its efficacy against influenza viruses A and B, parainfluenza, rhinovirus, respiratory syncytial virus, adenovirus, seasonal strains of coronaviruses, metapneumovirus, and herpes simplex viruses types 1 and 2 (cold sores, genital herpes) has been established experimentally and clinically. The drug reduces the concentration of the virus in affected tissues, influences the endogenous interferon system and associated cytokines, and induces the production of endogenous "early" interferons (IFN α/β) and gamma-interferon (IFN γ).

It stimulates both humoral and cellular immune responses. It increases antibody production (including secretory IgA), activates the functions of T-effectors and T-helper cells (Th), and normalizes their ratio. It enhances the functional reserve of Th and other cells involved in the immune response. It acts as an inducer of a mixed Th1 and Th2-type immune response: it increases the production of Th1 cytokines (IFN γ, IL-2) and Th2 cytokines (IL-4, IL-10), and normalizes (modulates) the balance of Th1/Th2 activities. It enhances the functional activity of phagocytes and natural killer (NK) cells.

The sensitivity of modern physicochemical analysis methods (gas-liquid chromatography, high-performance liquid chromatography, chromatographic mass spectrometry) does not allow for the assessment of the active substance content of the Anaferon® preparation in biological fluids, organs, and tissues, which makes the study of pharmacokinetics technically impossible.

Anaferon - 20 lozenges, recommended for the first symptoms of ARVI and influenza. This medication contains antibodies to viral proteins, which help strengthen the immune system and reduce the risk of disease recurrence. The tablets are intended for dissolution in the oral cavity, ensuring rapid action and improving treatment outcomes. Anaferon does not cause side effects and is suitable for the treatment of both adults and children. The medication has proven to be an effective means for the prevention and treatment of influenza and ARVI.